Triple-negative breast cancer (TNBC) is a clinically aggressive subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, leaving few targeted therapeutic options. Here, ESR1 is linked to triple-negative breast carcinoma.